IVERIC bio (Ophthotech)

^{Priced, Nasdaq: ISEE}

Late-stage biotech developing novel therapeutics for eye diseases.

Industry: Health Care

First Day Return: +19.5%

ISEE

Late-stage biotech developing novel therapeutics for eye diseases.

IPO News for IVERIC bio (Ophthotech)

It's electric: Spark Therapeutics increases proposed IPO deal size by 48% to $130 million 01/28/15
Sustained-release eye pharmaceutical Ocular Therapeutix files for a $86 million IPO 06/20/14
Rare eye disease biotech Applied Genetic Tech sets terms for $50 million IPO 03/12/14

IPO Data
IPO Date	09/24/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$167
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.ophthotech.com
Headquarters	New York, NY, United States
Founded	2007
Employees at IPO	22

IPO News for IVERIC bio (Ophthotech)

IVERIC bio (Ophthotech) (ISEE) Performance